Graves Disease Clinical Trials in Houston, Texas

7 studies are recruiting for graves disease in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease

   The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid

   Stage

   Phase 3

   Ages

   18 to 70

   Site

   Site-034, Houston, Texas

   Locations

   56 in total

   Run by

   Biohaven Therapeutics Ltd.

   See if you can join NCT07661056 on ClinicalTrials.gov

2. A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

   The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Juno Research, Houston, Texas

   Locations

   32 in total

   Run by

   argenx

   See if you can join NCT07570316 on ClinicalTrials.gov

3. A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old

   In this study, researchers will learn more about the use of felzartamab in participants with Graves' Disease, also known as GD. GD is an autoimmune disease, which means the body's immune system attacks its own healthy cells. In people with GD, the immune system produces abnormal antibodies, called …

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Gulf Coast Clinical Research, Houston, Texas

   Locations

   11 in total

   Run by

   Biogen

   See if you can join NCT07722546 on ClinicalTrials.gov

4. Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease

   This study is being conducted to look at the effect YB-101 has on thyroid function. This study will also evaluate how safe and well tolerated YB-101 is and how it is distributed through the body. The study consists of a part 1, blinded treatment period, and a part 2 double-blinded treatment period.…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Site 110, Houston, Texas

   Locations

   29 in total

   Run by

   Yarrow Bioscience, Inc.

   See if you can join NCT07682896 on ClinicalTrials.gov

5. A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

   This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 …

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Site Number - 1071, Houston, Texas

   Locations

   134 in total

   Run by

   Immunovant Sciences GmbH

   See if you can join NCT06727604 on ClinicalTrials.gov

6. A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

   This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Site Number - 1031, Houston, Texas

   Locations

   163 in total

   Run by

   Immunovant Sciences GmbH

   See if you can join NCT07018323 on ClinicalTrials.gov

7. Study of BHV-1300 in Graves' Disease

   The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   Site-106, Houston, Texas

   Locations

   18 in total

   Run by

   Biohaven Therapeutics Ltd.

   See if you can join NCT06980649 on ClinicalTrials.gov